Bioventus (BVS) Revenue (2020 - 2026)

Bioventus (BVS) has 7 years of Revenue data on file, last reported at $132.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 6.63% year-over-year to $132.1 million; the trailing twelve-month figure through Mar 2026 stood at $576.3 million (up 1.52% YoY), and the FY2025 full-year result was $568.1 million, down 0.91% from the prior year.
• Revenue for Q1 2026 stood at $132.1 million, down from $157.9 million in the prior quarter.
• Across five years, Revenue topped out at $157.9 million in Q4 2025 and bottomed at $117.3 million in Q2 2022.
• The 5-year median for Revenue is $135.4 million (2023), against an average of $135.2 million.
• The widest annual swing landed in 2022, when Revenue jumped 43.42%; it then retreated 6.12% in 2023.
• A 5-year view of Revenue shows it stood at $125.8 million in 2022, then climbed by 7.62% to $135.4 million in 2023, then advanced by 13.45% to $153.6 million in 2024, then advanced by 2.77% to $157.9 million in 2025, then dropped by 16.35% to $132.1 million in 2026.
• The last three Revenue figures came in at $132.1 million (Q1 2026), $157.9 million (Q4 2025), and $138.7 million (Q3 2025), per Business Quant data.

Peer Comparison